You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

Panitumumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for panitumumab
Recent Clinical Trials for panitumumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
MapKure, LLCPhase 1
ECOG-ACRIN Cancer Research GroupPhase 3
Vanderbilt-Ingram Cancer CenterPhase 1

See all panitumumab clinical trials

Recent Litigation for panitumumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd.2023-10-20
Sorrento Therapeutics, Inc. and Official Committee of Unsecured Creditors2023-02-13
Janssen Biotech, Inc. v. Amgen Inc.2022-11-29

See all panitumumab litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH et al.2019-12-20
2018-03-20
Forty Seven, Inc.2018-01-08

See all panitumumab litigation

Pharmacology for panitumumab
Mechanism of ActionHER1 Antagonists
Established Pharmacologic ClassEpidermal Growth Factor Receptor Antagonist
Chemical StructureAntibodies, Monoclonal
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for panitumumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for panitumumab Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Amgen Inc. VECTIBIX panitumumab Injection 125147 ⤷  Try for Free 2039-02-26 Company disclosures
Amgen Inc. VECTIBIX panitumumab Injection 125147 ⤷  Try for Free 2017-05-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for panitumumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for panitumumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122008000027 Germany ⤷  Try for Free PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203
300335 Netherlands ⤷  Try for Free PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071205
08C0022 France ⤷  Try for Free PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001 20071203
C00979246/01 Switzerland ⤷  Try for Free PRODUCT NAME: PANITUMUMABUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57872 14.10.2008
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for the Biologic Drug: Panitumumab

Introduction

Panitumumab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is a crucial treatment option for metastatic colorectal cancer (mCRC) and certain types of head and neck cancers. Here, we delve into the market dynamics and financial trajectory of panitumumab, highlighting key drivers, challenges, and future projections.

Market Size and Forecast

The panitumumab market was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.8 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 7.1% from 2024 to 2031[1].

Key Drivers of Market Growth

Increasing Prevalence of Colorectal Cancer

The rising incidence of colorectal cancer globally, driven by factors such as aging populations and lifestyle changes, significantly boosts the demand for panitumumab. This trend is expected to continue, fueling market growth[1].

Advancements in Oncology Therapies

Ongoing research and development in cancer treatments, particularly in targeted therapies like panitumumab, are expanding its use. New clinical trials and combination therapies also contribute to the increasing demand for this drug[1].

Growing Adoption of Targeted Therapies

As personalized medicine becomes more mainstream, targeted therapies like panitumumab are gaining traction over traditional chemotherapy. This shift towards personalized treatment options is driving the market forward[1].

Increasing Healthcare Expenditure

Higher investments in healthcare infrastructure, especially in developing countries, are facilitating better diagnosis and treatment access. This increased expenditure supports the demand for advanced biologic treatments like panitumumab[1].

Challenges and Limitations

High Treatment Costs

Panitumumab is expensive, with high costs associated with its development, production, and treatment. These costs limit accessibility, particularly in low- and middle-income regions[1].

Adverse Side Effects

Treatment with panitumumab is associated with significant side effects such as skin toxicity, diarrhea, and electrolyte imbalances. These side effects can reduce its adoption and may lead to discontinuation of therapy[1].

Emergence of Biosimilars

The introduction of biosimilar drugs that are more cost-effective poses a threat to the market growth of panitumumab. These alternatives provide similar efficacy at lower prices, reducing the demand for panitumumab[1].

Stringent Regulatory Approvals

Regulatory hurdles in obtaining approvals for new indications or modifications to existing treatments can slow down market growth. The process of ensuring safety and efficacy through clinical trials is time-consuming and costly[1].

Cost-Effectiveness and Economic Impact

Comparative Cost Analysis

Studies have shown that panitumumab can be a cost-effective option compared to other treatments. For instance, a cost-effectiveness analysis revealed that panitumumab resulted in an incremental cost of US $60,286 and an incremental quality-adjusted life-year (QALY) of 0.445, translating into a cost per QALY gained of US $135,391, making it a favorable option for first-line treatment of patients with wild-type RAS mCRC compared to bevacizumab[2].

Provincial Healthcare Costs

A Net Impact Analysis (NIA) in various Canadian provinces found that treating chemorefractory mCRC patients with panitumumab rather than cetuximab reduced healthcare resource costs. The total annual per patient cost of panitumumab ranged from $22,203-$32,600, which was lower than the costs associated with cetuximab treatment[5].

Market Segmentation

By End-User

The panitumumab market is segmented by end-users into hospitals, clinics, and ambulatory surgical centers. Hospitals are the largest segment, providing comprehensive healthcare services, including advanced diagnostic and therapeutic capabilities[1].

By Geography

The market is segmented geographically into North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. North America, particularly the United States, drives the market due to its robust healthcare infrastructure and strong adoption of targeted therapies. Europe and the Asia-Pacific region also contribute significantly to the market growth, with countries like China and India exhibiting high demand due to an expanding middle class and growing focus on cancer treatment options[1].

Key Players

Major players in the panitumumab market include Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Merck KGaA, and others. These companies are involved in ongoing research and development, which is crucial for the market's growth and expansion[1].

Impact of Personalized Medicine

Personalized medicine plays a significant role in the use of panitumumab. Genetic testing to identify patients with specific mutations, such as wild-type RAS, helps in targeting the treatment more effectively. This approach can reduce healthcare costs by avoiding trial-and-error dosing and minimizing adverse drug reactions[3].

Future Projections

Market Growth Potential

The panitumumab market is expected to continue growing, driven by increasing cancer prevalence, advancements in oncology therapies, and the growing adoption of targeted therapies. Despite challenges such as high treatment costs and the emergence of biosimilars, the market is projected to reach USD 1.8 billion by 2031[1].

Expanding Geriatric Population

The expanding geriatric population is another factor that will contribute to the market growth. As the population ages, the incidence of colorectal cancer is likely to increase, further boosting the demand for panitumumab[1].

Key Takeaways

  • The panitumumab market is projected to grow at a CAGR of 7.1% from 2024 to 2031.
  • Increasing prevalence of colorectal cancer and advancements in oncology therapies are key drivers of market growth.
  • High treatment costs and adverse side effects are significant challenges.
  • Personalized medicine and genetic testing are crucial for effective treatment and cost reduction.
  • The market is segmented by end-users and geography, with North America and Europe being major contributors.

FAQs

Q: What is the primary use of panitumumab?

A: Panitumumab is primarily used in the treatment of metastatic colorectal cancer (mCRC) and certain types of head and neck cancers.

Q: What are the key drivers of the panitumumab market growth?

A: The key drivers include the increasing prevalence of colorectal cancer, advancements in oncology therapies, growing adoption of targeted therapies, and increasing healthcare expenditure.

Q: What are the significant challenges facing the panitumumab market?

A: High treatment costs, adverse side effects, the emergence of biosimilars, and stringent regulatory approvals are significant challenges.

Q: How does personalized medicine impact the use of panitumumab?

A: Personalized medicine helps in identifying patients with specific genetic mutations, ensuring more effective treatment and reducing healthcare costs by minimizing adverse drug reactions.

Q: What is the projected market size of panitumumab by 2031?

A: The panitumumab market is projected to reach USD 1.8 billion by 2031, growing at a CAGR of 7.1% from 2024 to 2031.

Sources

  1. Verified Market Research - Panitumumab Market Size, Trends, & Forecast
  2. PubMed - A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab
  3. Personalized Medicine Coalition - The Case for Personalized Medicine
  4. Market Research Intellect - Global Panitumumab Market Size and Forecast
  5. PubMed - Comparative net cost impact of the utilization of panitumumab versus cetuximab in the treatment of metastatic colorectal cancer

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.